EUVIMEDEUVIMED entdecken
Leitlinie

ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy

John L McAfee, Raza S Hoda, Carrie Hoyle, Lauren McCoy, Cathy Sprague, Chandana A Reddy, Shlomo A Koyfman, Jessica L Geiger, Miglena K Komforti, Christopher C Griffith

Modern Pathology · 2023

DOI: 10.1016/j.modpat.2023.100273 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Modern Pathology, 2023. Verfasst von John L McAfee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Salivary Gland Neoplasms, Biomarkers, Tumor, Salivary Ducts. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Salivary duct carcinoma (SDC) is aggressive with limited therapeutic options. A subset of SDC display human epidermal growth factor receptor 2 (HER2) protein overexpression by immunohistochemistry, and some show ERBB2 gene amplification. Guidelines for HER2 scoring are not firmly established. Recent advances in breast carcinoma have established a role for anti-HER2 therapies in lesions with low HER2 expression lacking ERBB2 amplification. Delineating HER2 staining patterns in SDC is critical for evaluating anti-HER2 treatments. In total, 53 cases of SDC resected at our institution between 2004 and 2020 were identified. Androgen receptor (AR) and HER2 immunohistochemistry and ERBB2 fluorescence in situ hybridization were performed in all cases. AR expression was scored for percentage positive cells and categorized as positive (>10% of cells), low positive (1%-10%), or negative (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesSalivary Gland NeoplasmsBiomarkers, TumorSalivary DuctsHumansFemaleMaleMiddle AgedAgedGene AmplificationAdultImmunohistochemistryAged, 80 and overIn Situ Hybridization, FluorescencePractice Guidelines as TopicRetrospective StudiesReceptors, Androgen

Stichwörter der Autor:innen

ERRB2HER2androgen receptorfluorescence in situ hybridizationsalivary duct carcinomatrastuzumab

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanBiomarkers, TumorReceptors, Androgen

Autor:innen und Institutionen

  • Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.
  • Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida.
  • Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: griffic8@ccf.org.

Zitieren

APA

McAfee, J. L., Hoda, R. S., Hoyle, C., McCoy, L., Sprague, C., Reddy, C. A., Koyfman, S. A., Geiger, J. L., Komforti, M. K., & Griffith, C. C. (2023). ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy. Modern Pathology. https://doi.org/10.1016/j.modpat.2023.100273

Vancouver

McAfee JL, Hoda RS, Hoyle C, McCoy L, Sprague C, Reddy CA, et al. ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy. Modern Pathology. 2023. doi:10.1016/j.modpat.2023.100273

BibTeX
@article{McAfee2023,
  author = {McAfee, John L and Hoda, Raza S and Hoyle, Carrie and McCoy, Lauren and Sprague, Cathy and Reddy, Chandana A and Koyfman, Shlomo A and Geiger, Jessica L and Komforti, Miglena K and Griffith, Christopher C},
  title = {ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy},
  journal = {Modern Pathology},
  year = {2023},
  doi = {10.1016/j.modpat.2023.100273}
}
Kostenlos starten →